A new report from AHIP indicates that biosimilars have the potential to garner savings of $180 billion over 5 years, but there needs to be a review of the approval process for interchangeability to encourage more approvals.
The lone “no” vote came from Sen. Josh Hawley (R-Mo.), who argued that the U.S. has the choice between devoting more military resources to Europe, or doing “what we need to do in Asia to deter China – we cannot do both.”